Q2 2020 Orexo AB Earnings Call Transcript
Hello and welcome to the Orexo Interim Reports Q2 2020. (Operator Instructions) Today, I'm pleased to present Nikolaj Sørensen, CEO; and Joseph DeFeo, CFO. Please begin your meeting.
¸ - ()-&
Thank you very much and welcome to the second interim report. I will also say we have received some questions through e-mails and Lena Wange, who is our Investor Relations Director, who will join the call in the end for the Q&A session and ask these questions if they have not already been asked or addressed during the presentation.
So this quarter has, in many ways been a very exciting quarter for Orexo. We have invested into a completely new area in digital therapies where we, due to the circumstances with the COVID-19 pandemic, have had an opportunity and also both commercially and regulatory, to accelerate the launch of vorvida and for deprexis. We have also, during the quarter, seen that our R&D pipeline has progressed according to plan. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |